GSK PLC Raises Guidance After RSV Vaccine Lifts Earnings -- Update
01 Novembro 2023 - 5:20AM
Dow Jones News
By Ian Walker
GSK PLC raised its guidance after third-quarter net profit rose
mainly due to the U.S. launch of its Arexvy vaccine, although it
missed analysts' forecasts.
The British pharmaceutical giant said Wednesday that net profit
from continuing operations for the third quarter was 1.46 billion
pounds ($1.77 billion), boosted by the vaccine for respiratory
syncytial virus, or RSV, compared with GBP759 million a year
earlier and a company-compiled consensus of GBP1.87 billion.
Turnover for the period rose to GBP8.15 billion from GBP7.83
billion, beating analysts' expectations of GBP7.77 billion.
Third-quarter adjusted operating profit--one of the company's
preferred metrics which strips out exceptional and other one-off
items--rose 15% to GBP2.77 billion, while adjusted earnings per
share from continuing operations rose 17% to 50.4 pence.
For the year, GSK expects turnover to increase between 12% and
13% compared with previous guidance of 8% to 10% and adjusted
operating profit to increase between 13% and 15%, up from 11% to
13%. Adjusted earnings per share are forecast to rise between 17%
and 20% compared with 14% to 17%.
GSK has declared a dividend for the quarter of 14 pence a share
and reiterated that it expects to pay dividends of 56.5 pence a
share for the full year.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
November 01, 2023 04:05 ET (08:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024